To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

Inclusion Criteria:

* Clinically or pathologically proven metastatic breast cancer
* Eastern Cooperative Oncology Group performance status between 0-2
* Adequate bone marrow, renal and liver functions within normal limits
* Left ventricular ejection fractions more than 45% measured by multiple gated acquisition scan or echocardiogram within 6 weeks of randomization

Exclusion Criteria:

* Prior chemotherapy for metastatic disease (hormonal or chemotherapy in adjuvant setting and hormonal therapy in metastatic setting is allowed)
* Prior treatment with capecitabine or pegylated liposomal doxorubicin in the adjuvant setting (prior anthracyclines up to certain dose limit is allowed)
* Evidence of brain metastases unless previously treated and asymptomatic for 3 months or greater
* History of cardiac disease with New York Heart Association Class II or greater or clinical evidence of congestive heart failure
* Anthracycline resistant disease (locally recurrent or metastatic disease while on adjuvant anthracycline therapy or relapse less than 18 months after therapy completion)